Oasmia Pharmaceutical AB (STO: OASM) has decided to withdraw its MA for its Paccal Vet drug candidate for mastocytoma in dogs. European Medicines Agency asked for more data to assess the risk benefit profile of the paclitaxel reformulation.
The company says that the on-going approval process for the product in the USA is not affected. Oasmia develops new generation of drugs for human and veterinary oncology use. The stock has retreated 33% in early trading.
No comments:
Post a Comment